Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 15, 2021



Singular Genomics Systems, Inc.

(Exact name of registrant as specified in its charter)






(State or other jurisdiction
of incorporation)

(Commission File Number)

(IRS Employer
Identification No.)






10931 N. Torrey Pines Road, Suite #100
La Jolla, California 92037


(858) 333-7830
(Registrant’s address of principal executive offices

and telephone number, including area code)



(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class




Name of Each Exchange on Which Registered

Common Stock, par value $0.0001 per share




Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.





Item 7.01 Regulation FD Disclosure.

Andrew Spaventa, the Chief Executive Officer of Singular Genomics Systems, Inc. (the “Company”), and Eli Glezer, Ph.D., the Company’s Chief Scientific Officer, will participate in a webcast question and answer session about the Company at the 2021 Canaccord Genuity Virtual Medical Technology and Diagnostics Forum (the “Canaccord Genuity Presentation”). The Canaccord Genuity Presentation will be held on Thursday, November 18, 2021 at 8:00 AM Pacific Time.

There will be a live webcast of the Canaccord Genuity Presentation available on the News & Events section of the Company’s website at https://investor.singulargenomics.com/news-events/event-calendar, where any related slide presentations will be posted prior to the start of the webcast and a replay will be available following the live event.

The information in this Item 7.01 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.





Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.




Singular Genomics Systems, Inc.






November 15, 2021


/s/ Dalen Meeter




Dalen Meeter
Senior Vice President, Finance
Principal Financial Officer and Principal Accounting Officer